RxDoctor Payments Data

Chelsey Rice, NP

Acute Care · Rochester, NYNPI 1699413468

Payments from drug & device makers

$787in general payments, 2019–2025

Across 35 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$162
  • Kiniksa Pharmaceuticals, Ltd.$113
  • Boehringer Ingelheim$96
  • Cvrx, Inc.$73
  • Amgen$51
  • Novartis$43
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$787 in reported general payments places this provider in the 75th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$1,719
Medicare patients
20
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan43$50,018
EliquisApixaban30$40,333
JardianceEmpagliflozin28$28,392
FarxigaDapagliflozin Propanediol25$15,445
Atorvastatin Calcium94$1,515
Metoprolol Succinate67$920
Ezetimibe38$836
Carvedilol66$827
ClopidogrelClopidogrel Bisulfate35$414
Spironolactone63$396
Losartan Potassium22$312
Torsemide30$305
Metoprolol Tartrate25$305
Rosuvastatin Calcium22$288
Lisinopril24$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$43$50,01843 claims
PfizerEliquis$40$40,33330 claims
Boehringer IngelheimJardiance$96$28,39228 claims
AstraZenecaFarxiga$35$15,44525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 980 acute care providers in New York.

Other acute care in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →